(NewsDirect)
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chiefexecutive Tim McCarthy visited Thomas Warner at the Proactive Londonstudio after confirming to the market that the specialtybiopharmaceutical will be moving forward into a key phase 2/3 adaptiveclinical trial, alongside its US partners Avion Pharmaceuticals.McCarthy says that he's "absolutely delighted" to bemoving forward with the study and emphasises the significant potentialof its deal with Avion, including milestone payments of up to $70million and double-digit royalty percentages, in addition to obviousbenefit to patients. McCarthy also mentions ongoing discussions formore commercial partnerships and the potential for major breakthroughsin the future.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.